CMTM6 Stabilizes PD‐L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma

Kyohei Yugawa, Shinji Itoh, Tomoharu Yoshizumi, Norifumi Iseda, Takahiro Tomiyama, Akinari Morinaga, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Yoshinao Oda, Masaki Mori – 24 November 2020 – CKLF‐like MARVEL transmembrane domain containing 6 (CMTM6) was identified as a regulator of programmed death ligand 1 (PD‐L1), which induces antitumor immunity in several cancers. This study aimed to clarify the relationship between CMTM6 and PD‐L1 expression and clinical outcomes in patients with hepatocellular carcinoma (HCC).

Frailty Is a Risk Factor for Postoperative Mortality in Patients With Cirrhosis Undergoing Diverse Major Surgeries

Nadim Mahmud, David E. Kaplan, Tamar H. Taddei, David S. Goldberg – 23 November 2020 – With a rising burden of cirrhosis surgeries, understanding risk factors for postoperative mortality is more salient than ever. The role of baseline frailty has not been assessed in this context. We evaluated the association between patient frailty and postoperative risk among diverse patients with cirrhosis and determined if frailty improves prognostication of cirrhosis surgical risk scores. This was a retrospective cohort study of U.S.

Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation

Omar Y. Mousa, Brian D. Juran, Bryan M. McCauley, Mette N. Vesterhus, Trine Folseraas, Coleman T. Turgeon, Ahmad H. Ali, Erik M. Schlicht, Elizabeth J. Atkinson, Chang Hu, Denise Harnois, Elizabeth J. Carey, Andrea A. Gossard, Devin Oglesbee, John E. Eaton, Nicholas F. LaRusso, Gregory J. Gores, Tom H. Karlsen, Konstantinos N. Lazaridis – 23 November 2020

Organoids and Spheroids as Models for Studying Cholestatic Liver Injury and Cholangiocarcinoma

Keisaku Sato, Wenjun Zhang, Samira Safarikia, Abdulkadir Isidan, Angela M. Chen, Ping Li, Heather Francis, Lindsey Kennedy, Leonardo Baiocchi, Domenico Alvaro, Shannon Glaser, Burcin Ekser, Gianfranco Alpini – 22 November 2020 – Cholangiopathies, such as primary sclerosing cholangitis, biliary atresia, and cholangiocarcinoma, have limited experimental models.

Subscribe to